L OW-GRADE astrocytomas (WHO Grades I and II) are slow-growing neoplasms that constitute approximately 30% of primary brain tumors of glial origin. 4, 19 Among them pilocytic astrocytomas commonly develop in the pediatric population and fibrillary astrocytomas are frequently found in the young adults. These tumors are often considered histologically benign in nature. Although the initial mortality rate associated with these tumors is not high, some of them can transform into fast-growing, high-grade tumors. 12, 14 Surgery is often the primary treatment; however, radical tumor removal is not always feasible because of the infiltrative nature and eloquent locations of some tumors. Fractionated radiotherapy is also frequently used after surgery for residual neoplasms. Chemotherapy for these tumors has also been reported. 3, 17 Despite all these treatments, local failure can still be seen several years later. [5] [6] [7] [8] Local recurrence after
Abbreviations used in this paper: ARE = adverse radiation effect; GKS = Gamma Knife surgery; MR = magnetic resonance; WHO = World Health Organization. multimodality treatment remains a challenge especially in pediatric patients.
Stereotactic radiosurgery provides noninvasive, accurate delivery of focused high-dose radiation to brain tumors as a primary, adjuvant, or salvage treatment. Low-grade astrocytomas are relatively circumscribed, as demonstrated on MR images. 20 Hence, patients harboring these tumors may be good candidates for GKS. There were a few reports on treating astrocytomas with GKS, which have appeared in the literature. 2, 9, 10, 13 At our hospital we started in 1993 to treat some selected patients with astrocytomas by using GKS. This study is aimed at reviewing our treatment results and presenting our experience in performing GKS in this group of patients.
Clinical Material and Methods

Patient Population
From 1993 to 2003, there were 21 patients with 25 histologically proven low-grade astrocytomas who were treated by GKS at the Taipei Veterans General Hospital. The criteria for patient selection were small tumor volume (Ͻ20 ml), deep-seated or eloquent tumor location, and a relatively well-defined tumor margin. The median age of the patients was 20 years (range 6-70 years). Four patients underwent treatment of two tumors during a single GKS procedure. The characteristics of these patients with Grade I and II astrocytomas are shown in Table 1 . In the Grade I group, there were five pilocytic astrocytomas and three subependymal giant cell astrocytomas (two of them associated with tuberous sclerosis). Fifteen patients underwent one or more tumor resections before GKS. Seven patients received fractionated cranial radiotherapy (40.3-50 Gy) before GKS, including two patients who were already scheduled to undergo GKS as a treatment boost 13 and 30 days, respectively, after radiotherapy. The radiotherapy dose fractionation in one of these patients was 40.3 Gy in 34 fractions, and 48 Gy in the other. Four patients underwent stereotactic biopsy sampling only without craniotomy before GKS. One patient received chemotherapy after tumor resection. Other procedures before GKS included the placement of two ventriculoperitoneal shunts and one Ommaya reservoir.
Radiosurgical Technique
For most patients, a stereotactic Leksell headframe (Elekta Instruments AB, Stockholm, Sweden) was affixed after the patient received a local anesthetic and before MR imaging was performed. General anesthesia was induced after endotracheal intubation in patients younger than 10 years of age. Magnetic resonance imaging was performed with and without Gd contrast enhancement. Target delineation was based on T 1 -and T 2 -weighted images and on the consensus of a team of neuroradiologists, neurosurgeons, and radiation oncologists. The treatment planning software used was KULA (Elekta Instruments AB) for four patients and Leksell GammaPlan (Elekta Instruments AB) for 17 patients. Our Gamma Knife unit was a model B (Elekta Instruments AB). Multiple isocenters with different collimator sizes were chosen to make the dose distribution as conformal as possible. The radiosurgical data are shown in Table 2 . The prescription doses delivered in the two patients undergoing combined GKS and radiotherapy were 11.5 and 8 Gy, respectively. Patients were discharged from the hospital the day after treatment.
Follow-Up Study
All patients were observed at our neurosurgery department or Cancer Center for clinical and MR imaging evaluations at 3-to 6-month intervals during the first 2 years and annually thereafter. In patients in whom neurological deterioration occurred, MR imaging studies were arranged immediately.
Statistical Analysis
The definition of progression-free survival was based on MR imaging-demonstrated obvious tumor shrinkage or absence of tumor enlargement after the treatment. Patients with shrinkage of solid components but enlargement of cysts were still considered progression free. The progression-free patient survival was calculated using the Kaplan-Meier method. The log-rank test was used for comparison of survival curves. Statistical analyses were performed using SPSS software (version 12.0, SPSS Inc., Chicago, IL). Results were considered significant with probability values less than 0.05.
Results
Tumor Response
One patient was lost to follow-up review. Eighty percent of our patients underwent at least four follow-up MR imaging studies. The median MR imaging follow up was 49 months (range 4-144 months) after GKS. The median clinical follow-up time after GKS was 67 months (range 5-144 months). The tumor response in the 20 patients, based on MR imaging findings, is shown in Table 3 . All patients with pilocytic astrocytomas were free from tumor progression and the longest follow up for that group was 105 months. The common MR imaging finding after GKS was gradual shrinkage of the tumors. A few tumors had exhibited transient swelling with perifocal edema, examples of which are shown in Figs. 1 through 3 . In one patient in whom the cyst enlarged, stereotactic aspiration of the fluid was performed 7 months after GKS and the solid component continued to shrink, as demonstrated on follow-up MR images (Fig. 2) .
Failure Pattern and Salvage Treatment
In six patients the tumor progressed 4 to 55 months (median 16 months) after GKS. The histological composition of the tumors in this group of patients included three subependymal giant cell tumors and three Grade II astrocytomas. All but one patient had undergone craniotomy before GKS. The median tumor volume in these patients was 1.7 ml (range 0.5-7.7 ml).The median prescription dose was 14.8 Gy (range 14.5-15 Gy). All of the tumor progression occurred within the radiation volume. Five patients underwent craniotomy and one patient also received fractionated radiotherapy for further salvage treatment.
Treatment Complications
No procedure-related deaths occurred. Adverse radiation effects revealed on MR images were defined as the abnormal increasing T 2 -weighted changes surrounding the tumor, which indicated a disruption of the blood-brain barrier developing after GKS. Mild-to-moderate AREs were found in eight patients (40%). Most of these patients had mild or no symptoms. Prescription dose, tumor volume, and previous cranial radiotherapy may have influenced the occurrence of AREs after GKS. Of 13 patients who had not undergone previous cranial radiotherapy and in whom tumors received margin doses of 11 to 16 Gy (median 14.5 Gy), only two of them (15%) developed any AREs. Conversely, four (57%) of the seven patients who underwent radiotherapy before radiosurgery (margin doses 8-18 Gy, median 12 Gy) developed AREs. Not surprisingly, MR imaging performed in the two patients who underwent GKS as a treatment boost combined with radiotherapy both developed AREs. An example of the MR imaging-documented AREs is shown in Fig. 3 . This patient recovered gradually from the initial complications of bilateral oculomotor neuropathy and her pretreatment symptoms of diplopia and ptosis finally improved. No significant late complications were seen for those two patients receiving radiotherapy and GKS boost. In the other 12 patients in whom tumor progression was not seen, one patient had inferior quadrantanopia, one experienced facial palsy and diplopia, and one had persistent seizures after GKS.
Overall and Progression-Free Survival
One patient with a Grade II astrocytoma died of disease 41 months after GKS, even after additional salvage craniotomy. Excluding the one patient lost to follow up, all the other patients are still alive. The longest follow-up time in these patients is 12 years. The 10-year progression-free patient survival after GKS in this study is 65% (Fig. 4) . The two patients who underwent radiotherapy and radiosurgery as a treatment boost had no tumor progression for 73 and 82 months.
Discussion
Treatment Choices for Low-Grade Astrocytomas
For patients with WHO Grade I and II astrocytomas, the selection of treatment usually depends on tumor location, size, pathological characteristics, and clinical scenario. Complete resection of circumscribed tumors can usually provide long-term patient survival. Even after partial removal of pilocytic astrocytomas, patients can be monitored with periodic imaging examinations, and surgery or adjuvant treatment is usually not indicated unless tumors recur. Partial resection for Grade II astrocytomas and adjuvant radiotherapy in these patients can be helpful but carries the risk of radiation-induced brain damage and chronic neurological deficits. The potential adverse effects of radiotherapy on mental development is of particular concern in children. 16 Gamma Knife surgery is characterized by a rapid dose falloff in the normal brain tissue surrounding the tumors and thus should be considered for the treatment of small low-grade astrocytomas developing in deep-seated structures such as the brainstem, cerebellar vermis, thalamus, or other eloquent areas or in the setting of tumor recurrence after craniotomy.
Efficacy of GKS
Kida, et al., 13 treated 51 patients with low-grade astrocytomas by using GKS and achieved a control rate of 91.7% for Grade I astrocytomas and 87.2% for Grade II tumors during a mean follow-up period of 27.6 months. Hadjipanayis, et al., 9 treated 37 patients with pilocytic astrocytomas by using GKS and achieved a tumor control rate of 67.6% with a median follow-up period of 28 months. Bothius, et al., 3 treated 12 patients with pilocytic astrocytomas and all tumors were under control at a median neuroimaging follow-up time of 4.7 years. In this retrospective study with the longest follow-up time of up to 12 years and a median follow-up time of 5.5 years, the long-term efficacy of GKS for the treatment of low-grade astrocytomas was underscored by the high tumor control rate of 70% (14 of 20 patients), which is compatible with the results of other studies.
Optimal Dose of GKS for Tumor Control
A review of the literature revealed that the prescription dose for single-fraction GKS to treat low-grade astrocytomas ranged from 9 to 22.5 Gy.
2,9,10,14 Dose ranges from 12 to 16 Gy were commonly administered. It is remains unclear whether Grade II astrocytomas require a higher dose for control than do Grade I tumors. In this study, the prescription dose to the tumor margin, which ranged from 11 to 18 Gy (not combined with radiotherapy), was thought to be effective for most of our patients with lowgrade astrocytoma. It should be noted, however, that previously MR imaging-documented AREs can still be seen in some patients, especially in the two patients who underwent GKS boost treatment after fractionated radiotherapy. In determining the prescription dose, tumor size and location and the patient's treatment history should be considered. Our prescription dose has actually declined from the range of 15 to 18 Gy in the KULA period (1993) (1994) (1995) (1996) to 11 to 14.5 Gy in the GammaPlan period (after 1996). The major reason to decrease the prescription dose is to lessen the potential acute and late radiation-related side effects but still maintain the same tumor control rate. When the tumor margin dose was within the 11-to 14.5-Gy range, we found that only one (11%) of nine patients who had not received previous cranial radiotherapy developed AREs, and tumor progression was noted in three (25%) of 12 patients.
Combined Treatment: Radiotherapy and GKS
For the two patients who underwent combined fractionated radiotherapy and GKS boost treatment, the treatment rationale was 1) to give a fractionated dose to the clinical target volume that included a zone of microscopic infiltrating astrocytoma cells surrounding the gross tumor volume and the gross tumor volume per se; and 2) to boost treatment with a single dose to the gross tumor volume by using GKS. Authors of radiobiology studies have reported that fractionated radiotherapy is beneficial in inducing better repair of normal tissue and in reoxygenation and redistribution to higher radiosensitivity phases of the cell cycle of proliferating tumor cells. 11 Theoretically this combination will decrease the chance of recurrence at the tumor margin. In this study, there was no recurrence at the tumor margin in any patient treated with GKS alone. The optimal dose of GKS when combined with radiotherapy remains to be determined. Perhaps the margin dose should be reduced to less than 10 Gy to prevent severe AREs. Because we treated only two patients with combined GKS and radiotherapy, it is difficult to make a meaningful recommendation. The answer to the question of whether the combination of fractionated radiotherapy and GKS can achieve better control of low-grade astrocytomas than GKS alone awaits future prospective randomized trials.
Prognostic Factors
In this study involving a limited number of patients, it was not possible to perform multivariate analysis for evaluation of prognostic factors; however, anecdotally, we did not see any significant difference in progression-free survival in terms of patient age, tumor volume, tumor grade, or prescription dose. Kida and coworkers 13 reported that patients who were older than 10 years of age and harbored a Grade I tumor had a better response after GKS at more than 24 months follow up. In another group of patients with pilocytic astrocytomas, Hadjipanayis, et al., 9 found that older patient age, multifocal lesions, and failure of previous fractionated radiotherapy portended a poor prognosis after GKS; however, only a univariate analysis was performed.
In a large case series of 401 patients with low-grade gliomas treated by stereotactic radiotherapy, Bauman, et al., 1 found that the variables good pretreatment Karnofsky Performance Scale score (≥70), patient age 18 to 40 years, presence of seizures at presentation, and absence of contrast enhancement on pretreatment computerized tomography or MR images were associated with better overall patient survival. Plathow, et al., 18 reported that overall survival and progression-free survival of patients with lowgrade astrocytomas were significantly correlated with the absence of contrast media enhancement before stereotactic radiotherapy. Conversely, Marcus, et al., 15 found that contrast enhancement of low-grade gliomas on computerized tomography scans before radiotherapy was seen in most of their patients and was not prognostic for tumor progression or patient survival. In our study, contrast enhancement of tumors on MR images was also seen in 86% of our patients. Whether the contrast enhancement of lowgrade astrocytomas on imaging studies has any prognostic implications remains to be investigated in future studies.
Conclusions
Gamma Knife surgery provides durable local tumor control in selected patients with low-grade astrocytomas and the attendant radiation toxicity is acceptable. Dose modification or reduction should be considered for patients who have undergone fractionated cranial radiotherapy before radiosurgery. More patient data and longer follow-up times are needed for further elucidation of the radiosurgical effects on these tumors.
